Table 5.
Number of amino acids mutations observed in six different regions from NS5A protein, at baseline mean ± SD
NS5A region (aa range) | 2 groups (D0) (n = 147) | SVR (D0) (n = 99) | NR (D0) (n = 48) | SVR (M3) (n = 51) | NR (M3) (n = 32) | NR (M6) (n = 26) |
ISDR (2209-2248) | 1.5 ± 1.6 | 1.3 ± 1.7 | 1.9 ± 1.1 | 0.8 ± 0.8 | 2.1 ± 1.0 | 1.8 ± 1.2 |
PKRbd (2209-2274) | 5.4 ± 2.1 | 5.3 ± 2.4 | 5.7 ± 1.2 | 4.7 ± 1.6 | 6.1 ± 1.0 | 5.7 ± 1.3 |
V3 (2353-2379) | 5.5 ± 1.4 | 6.0 ± 1.5 | 4.7 ± 0.6 | 6.1 ± 1.3 | 4.8 ± 0.7 | 5.1 ± 0.6 |
Complete NS5A (1973-2208) | 32.6 ± 5.6 | 33.9 ± 6.0 | 29.8 ± 3.7 | 31.7 ± 5.3 | 30.8 ± 3.9 | 31.9 ± 2.9 |
N-terminal part of NS5A (1973-2208) | 12.4 ± 3.1 | 12.9 ± 3.3 | 11.6 ± 2.4 | 11.7 ± 2.0 | 11.2 ± 2.1 | 12.8 ± 2.1 |
C-terminal part of NS5A (2209-2419) | 20.1 ± 3.9 | 21.1 ± 4.1 | 18.2 ± 2.4 | 20.1 ± 4.2 | 19.6 ± 2.9 | 19.4 ± 3.4 |
n: number of PCR products analyzed; SVR: Sustained Responders; NR: Non-Responders to IFN-ribavirin therapy; D0: beginning of the treatment; M3: 3 mo of treatment; M6: 6 mo of treatment.